Emricasan

{{Drugbox | IUPAC_name = (3S)-3-{[(2S)-2- {[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | image = Emricasan_structure.png | image_class = skin-invert-image | tradename = |…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

{{Drugbox | IUPAC_name = (3S)-3-{[(2S)-2- {[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | image = Emricasan_structure.png | image_class = skin-invert-image | tradename = | legal_US = Investigational New Drug | legal_status = | bioavailability = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 254750-02-2 | PubChem = 12000240 | UNII_Ref = | UNII = P0GMS9N47Q | DrugBank_Ref = | ChemSpiderID = 10172707 | KEGG = D10004 | C=26 | H=27 | F=4 | N=3 | O=7 | SMILES = C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C | StdInChI = 1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1 | StdInChIKey = SCVHJVCATBPIHN-SJCJKPOMSA-N }} Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010.

Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization. The substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects.…

{{Drugbox | IUPAC_name = (3S)-3-{[(2S)-2- {[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid | image = Emricasan_structure.png | image_class = skin-invert-image | tradename = | legal_US = Investigational New Drug | legal_status = | bioavailability = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 254750-02-2 | PubChem = 12000240 | UNII_Ref = | UNII = P0GMS9N47Q | DrugBank_Ref = | ChemSpiderID = 10172707 | KEGG = D10004 | C=26 | H=27 | F=4 | N=3 | O=7 | SMILES = C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C | StdInChI = 1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1 | StdInChIKey = SCVHJVCATBPIHN-SJCJKPOMSA-N }} Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010.

Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization. The substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects.

It was developed for the treatment of liver disease and has been granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis cirrhosis The substance is the first pan-caspase inhibitor to advance to broad clinical testing, and its novel mechanism of action has led to research using it for other potential applications.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370837739 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.